Live
FierceBiotechPredicting Clinical Seizure Liability Earlier in Drug DevelopmentFierceBiotechScaling Radioligand Therapy: Expanding the Impact of TheranosticsFierceBiotechLilly further embraces Insilico’s AI tech, inking R&D collab worth up to $2.75BEndpoints NewsKailera plans IPO for Phase 3 obesity drug from HengruiEndpoints News#ACC26: Merck leans toward lower Winrevair dose in Phase 3 trial for rare form of heart failureThermo FisherWedge Capital Management L L P NC Sells 6,634 Shares of Thermo Fisher Scientific Inc. $TMO - MarketBeatWatersWaters Corporation Q2 2013 Financial Results Webcast Invitation - AOL.comWatersSG Americas Securities LLC Acquires 31,459 Shares of Waters Corporation $WAT - MarketBeat10x Genomics BlogIs Ark Invest’s Steady Buying Reframing the Long-Term Product Expansion Story At 10x Genomics (TXG)? - simplywall.stEndpoints News#AAD26: Biogen declares Phase 2 lupus success for anti-BDCA2 antibodyFierceBiotechTakeda clears path to FDA with phase 3 data on $4B psoriasis betCellAdvancing precision health discovery in a genetically diverse health system
FierceBiotech Mar 30, 2026

Predicting Clinical Seizure Liability Earlier in Drug Development

Predicting Clinical Seizure Liability Earlier in Drug Development

Original
Body unavailable. Use the original source.

Directory

59 All